Funded Tech Companies
ILiAD Biotechnologies
Researching who provided funding to ILiAD Biotechnologies? Knott Partners, private investors and Network-1 Technologies joined the equity holders in this biopharmaceutical company.
Company Overview
Company Name
ILiAD Biotechnologies
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
230 East 15th St. 1-A
New York, NY 10003
USA
New York, NY 10003
USA
Phone
Website
Email Address
Company Background Information
Overview
ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate is BPZE1, a live attenuated pertussis vaccine that is currently in Phase 2 and has successfully completed two Phase 1 human clinical trials.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
9/6/2022
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keith Rubin
Chief Financial Officer
Walter Greenblatt
Chief Operating Officer
Ken Solovay
Controller
James Ramadei
General Manager
Marcel Thalen
Vice President
Stanley Kim
Company Investors
- Knott Partners
- Network-1 Technologies (Corey Horowitz)
- Seedlings Life Science Ventures
- JEMS Venture Capital
- SDS Capital Partners
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs